Pharmacological Treatment of Addictive Disorders Larissa Mooney, M.D. Assistant Professor of Psychiatry UCLA Integrated Substance Abuse Programs.

Slides:



Advertisements
Similar presentations
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
Advertisements

Pharmacologic Treatment Options for Alcohol Dependency Damon Landreau, D.O. LCDR/USPH/USCG Flight Surgeon.
Drugs For Treating Drug Addiction Barry Zevin MD Tom Waddell Health Center San Francisco Department of Public Health Homeless Programs Board Certified.
Nicotine Addiction Pharmacy Practice II Winter 2005.
Addiction A-Pharmacological approaches to treating drug dependence B-Clinical use of drugs in substance dependence.
Evidence-Based Guidelines for Pharmacotherapy in Alcohol Dependence Chandan Nayak, MD Addiction Fellow University of Michigan Department of Psychiatry.
Medication Assisted Treatment: An Introduction Deborah A. Orr, Ph.D., RN Remington College School of Nursing.
Vaccination For Treatment of Cocaine Dependence Thomas A. Nguyen, M.D. University of Cincinnati, College of Medicine 1 © AMSP 2011.
Smoking Cessation. Opportunity for Physicians 70 percent of smokers want to quit. Without assistance only 5 percent are able to quit. Most try to quit.
Treating Nicotine Dependence in Patients with Addictive Disorders Eric Heiligenstein, M.D. Director of Psychiatry University Health Services University.
Ken Wassum & Abigail Halperin Session 13: Behavioral Counseling and Pharmacotherapy 09/14/2011.
for the Psychiatry Clerkship is proud to present And Now Here Is The Host... Insert Name Here.
Pharmacotherapy for Alcohol Dependence Clinical Addiction Research and Education Unit Section of General Internal Medicine Boston University Schools of.
Medication Development for Methamphetamine Dependence
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
Medication Assisted Treatment for Alcohol and Opioid Dependence Larissa Mooney, M.D. Assistant Professor of Psychiatry UCLA Integrated Substance Abuse.
Copyright Alcohol Medical Scholars Program1 The Relationships Between Alcohol Use Disorders and Nicotine Dependence Margaret Rukstalis, M.D. University.
Check your homework answers for the evaluation points of the Theory of Planned Behaviour: A strength of the theory of reasoned action (TPB) is that it.
Truman Medical Center Behavioral Health Evidence Based Practices Integrated Dual Disorder Treatment (IDDT)
DOUGHNUTSDOUGHNUTS. Opioid Agonist Therapy The Skinny on Methadone et al.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Results of the Vivitrol Pilot in Los Angeles County Presented by: Desiree A. Crevecoeur-MacPhail, Ph.D. Research Psychologist, UCLA ISAP.
Nicotine Holley Williamson and Rachel Martinez. Addiction Chewed, Smoked, or Inhaled Absorbed within 7 Seconds of inhalation Nicotine molecule shaped.
Pharmacological Treatment of Addictive Disorders Larissa Mooney, M.D. Assistant Professor of Psychiatry UCLA Integrated Substance Abuse Programs.
Drugs used in treatment of addiction
1 Smoking Cessation: What works and why… A Medical Model Stephen I Rennard University of Nebraska Florianopolis, Brazil October 2009.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
1 Impaired Decision Making In Substance Use Disorders Claire Wilcox MD UNM Dept of Psychiatry Alcohol Medical Scholars Program © AMSP.
Primary Care Conference Case Presentation: A New Smoking Cessation Treatment Option 25 October 2006 Douglas E. Jorenby, Ph.D.
Substance Use Disorders. A maladaptive pattern of substance use leading to clinically significant social, emotional, or occupational impairment or distress.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Drug addiction – learning gone wild? Dr Stuart McLaren MRCPsych. Phase 1 Psychopharmacology module
Pharmacotherapy for Alcohol Dependence
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Physiology and Behaviour of Withdrawal Syndrome Idrees M, Hussain A, Hyman A, Humphries R & Hughes E. Introduction: Chronic administration of certain drugs.
Brain diseases: Substance abuse and co-occurring disorders Mark Publicker, MD FASAM.
Buprenorphine {Suboxone®, Subutex®}
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
1 Varenicline for smoking cessation Robert West University College London Logroño, October
Chapter 5 Drugs of Abuse Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.
1 Use of Pharmacotherapies by Substance Abuse Treatment Facilities November 2007 Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration.
September 2015 PHARMACOLOGY OF ADDICTIONS.  Understanding the pharmacological basis of medications used to manage dependence  Understanding how pharmacological.
Addressing Tobacco Use in Mental Health Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester.
Addressing Tobacco Use in Medical Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester School.
Drugs used in treatment of addiction. What is Addiction? It is well known that the initial decision to use drugs is voluntary Addiction is a chronic,
Medication Assisted Treatment for Opioid Use Disorders
가톨릭대학교 성가병원 신경정신과 금연클리닉 김 대 진
Michael Fishman, MD Director of Young Adult Program Talbott Recovery Challenges Facing CRC’s and Young Adults in Recovery.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
1 Addiction to tobacco Robert West University College London November
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
December 10, 2015 Arthur Robin Williams MD MBE American Academy of Addiction Psychiatry Division on Substance Abuse Department of Psychiatry, Columbia.
November 23, 2015 Arthur Robin Williams MD MBE American Academy of Addiction Psychiatry Division on Substance Abuse Department of Psychiatry, Columbia.
Medication Assisted Treatment Daniel T. Brown, D.O. Medical Director, Meridian HealthCare.
Gregory S. Brigham, Ph.D., CEO
Smoking Cessation Medication
6 myths and facts about tobacco use disorder in people with mental health and substance use disorders Associate Professor.
Medication Assisted Treatment
screening, brief intervention, and referral to treatment
ADHD.
List Three Mechanisms by which Chronic Opioid Therapy Can Worsen Pain
Chapter 38 Drug Abuse II: Alcohol 1.
Impaired Decision Making In Substance Use Disorders
Assessing Opioid Use Disorder, part 1
CNS Stimulants Defination
Andrew Giannotti, M.D., FASAM
Pharmacologic Interventions for Unhealthy Drinking
Medications used in Treatment of Alcohol and Drug Use Disorders
Presentation transcript:

Pharmacological Treatment of Addictive Disorders Larissa Mooney, M.D. Assistant Professor of Psychiatry UCLA Integrated Substance Abuse Programs

Objectives Introduction to medication treatment approaches for addictive disorders Pharmacological treatment options within drug classes: –Alcohol –Opioids –Nicotine –Stimulants Clinical implications of co-occurring psychiatric disorders

Introduction Addiction is a chronic, relapsing brain disease characterized by compulsive use despite harmful consequences Pharmacotherapy as part of multimodal treatment plan Treatment approaches: –Medications (Bio) –Therapy, lifestyle changes (Psycho-Social) Thorough evaluation and diagnosis essential

Addiction Risk Factors

Neurobiology of Addiction Reward system: mesolimbic dopamine pathway –Natural vs. drug rewards –Dopamine release: pleasure and reinforcement Dopaminergic projections from ventral tegmental area (VTA) to nucleus accumbens (NA), amygdala, and prefrontal cortex (PFC) Process of addiction causes dysfunctional learning and memory and maladaptive behavioral patterns “Hypo-frontality”: impaired decision-making, loss of control (orbitofrontal cortex, anterior cingulate) Altered neurocircuitry: relapse risk even after extended periods of abstinence

Reward pathway -- mesolimbic dopamine system

Pharmacotherapy in Substance Use Disorders Treatment of withdrawal (“detox”) Treatment of psychiatric symptoms or co- occurring disorders Reduction of cravings and urges Substitution therapy Prevention

Medications for Alcohol Dependence FDA-Approved: –Disulfuram (Antabuse) –PO naltrexone (Revia) –IM naltrexone (Vivitrol) –Acamprosate (Campral) Non-FDA-approved: –Topiramate (Topamax) –Ondansetron (Zofran)

Disulfuram (Antabuse) FDA approved 1951 Dosing: 250mg-500mg qd Mechanism: inhibits aldehyde dehydrogenase, causing buildup of acetaldehyde with alcohol ingestion: –Flushing, nausea, vomiting, dizziness, dyspnea, diaphoresis, headache, palpitations –In severe cases: arrhythmias, seizures, coma, cardiovascular collapse

Disulfuram (Antabuse) Reactions may occur 1-2 weeks after last dose Caution: “hidden” alcohol in perfumes, mouthwash, cough medicines, desserts, sauces, salad dressings Side effects: fatigue, headache, hepatitis, psychosis (dopamine), neuritis, rash, aftertaste Most likely to benefit: highly motivated and directly observed patients Neiderhofer and Staffen ’03a: increased abstinence with disulfuram in adolescent alcoholics

Naltrexone (Revia) FDA approved 1994 Dosing: 50 mg PO qd (start at 25 mg qd) Mechanism: mu-opioid antagonist –Decreases positive reinforcing effects –Decreases cue- and alcohol-induced cravings Side effects: nausea, dysphoria, increased LFTs Results: fewer drinking days, less alcohol consumed, decreased craving Deas et al., ’05: pilot study in adolescent alcoholics

IM Naltrexone (Vivitrol) FDA approved 2006 Dose: 380 mg IM q 4 weeks No need for oral lead-in Stop drinking 7 days prior (ideal) Mechanism: opioid antagonist Results: Decreased heavy drinking days, decreased frequency of drinking

Acamprosate (Campral) FDA Approved 2004 Dose: 666mg PO tid Renal excretion Structural analog of amino acid taurine and GABA Mechanism: NMDA receptor modulation –Restores GABA-glutamate balance Blocks “negative” reinforcement

Acamprosate (Campral) Start post-detox (ideal) Side effects: diarrhea, abdominal discomfort Results: increased time to relapse, increased total abstinence, reduced drinking days Niederhofer and Staffen ’03: increased abstinence in adolescents with AUDs relative to placebo

Treating Opioid Dependence: Aims Detoxification: –Opioid-based agonist (methadone, buprenorphine) –Non-opioid based (clonidine, supportive meds) –Antagonist-based (naltrexone: “rapid”) Relapse prevention: –Agonist maintenance (methadone) –Partial agonist maintenance (buprenorphine) –Antagonist maintenance (naltrexone) Lifestyle and behavior change

Opioid Detoxification Medications used to alleviate withdrawal symptoms: - Opioid agnonists (methadone, buprenorphine) - Clonidine (alpha-2 agonist) Dose: 0.1 mg PO tid (increase as tolerated) Caution: hypotension - Other supportive meds anti-diarrheals, anti-emetics, ibuprofen, muscle relaxants, BDZs

Opioid Substitution Goals Reduce symptoms & signs of withdrawal Reduce or eliminate craving Block effects of illicit opioids Restore normal physiology Promote psychosocial rehabilitation and non- drug lifestyle

Methadone: Clinical Properties Orally active synthetic μ agonist Action: CNS depressant/ Analgesic Quick absorption, slow elimination, long half-life Effects last 24 hours; once-daily dosing maintains constant blood level Prevents withdrawal, reduces craving and use Facilitates rehabilitation Clinic dispensing limits availability

Buprenorphine for Opioid Dependence FDA approved 2002, age 16+ Mandatory certification from DEA (100 pt. limit) Mechanism: partial mu agonist Office-based, expands availability Analgesic properties Ceiling effect Lower abuse potential Safer in overdose

Buprenorphine Formulations Sublingual administration Subutex (Buprenorphine) -2mg, 8mg Suboxone (4:1 Bup:naloxone) -2mg/0.5 mg, 8mg/2mg Dose: 2mg-32mg/day

Buprenorphine: Pharmacological Characteristics Partial Agonist (ceiling effect) -less euphoria -safer in overdose High Receptor Affinity -long duration of action -1 st dose given during withdrawal

Medications for Nicotine Dependence FDA approved in adults: - Nicotine replacement therapies Patch, gum, lozenge, inhaler - Bupropion SR (Zyban) - Varenicline (Chantix) Some efficacy but not FDA approved: - Nortriptyline - Clonidine

Nicotine Patch OTC Dosing: 7, 14, and 21 mg > 10 cig’s/day: 21 mg < 10 cig’s/day: 14 mg 24 or 16 hour dosing Stop smoking at onset Side effects: skin reaction, insomnia

Nicotine Gum OTC 2mg if < 25 cig’s/day 4mg if > 25 cig’s/day Use q 1-2 h “Park” and chew method Slow, buccal absorption Avoid eating/drinking Side effects: mouth/throat soreness

Nicotine Lozenge OTC 2mg if 1 st cigarette > 30 min after waking 4mg if 1 st cigarette < 30 min after waking Up to 20 lozenges/day More discrete than gum

Bupropion SR (Zyban) Dose: 150 mg PO bid -if < 90 lbs, 150 mg qd max Start 5-7 days before quit date Mechanism: -NE and dopamine reuptake inhibition -Nicotinic receptor antagonism Side effects: headache, insomnia Contraindications: seizures, eating disorders Muramoto et al., ’07: efficacy of 300 mg dose relative to placebo in adolescents

Varenicline (Chantix) Dosing: Starter Pak, Continuing Pak (0.5 mg qd to 1 mg bid) for 12 weeks Start 7 days before quit date Mechanism: partial nicotinic agonist –Attenuates withdrawal –Decreases Craving Side effects: nausea, headache, insomnia Renal clearance (primary) Caution: risk of mood disturbance, suicidality

Stimulants CRACK METHAMPHETAMINE COCAINE

Methamphetamine vs. Cocaine Methamphetamine synthetic high lasts 8-24 hours T ½: 12 hours mechanism: both DA reuptake and release limited medical uses neurotoxicity Cocaine plant-derived high lasts minutes T ½: 1 hour mechanism: mainly DA reuptake used medically not directly neurotoxic

Medications Considered for Cocaine Negative Results+/Under Consideration Desipramine* Modafinil Amantadine*Disulfuram Gabapentin Propanolol (WD) Bupropion*Topiramate Baclofen TA-CD Vaccine

Medications considered for Methamphetamine Negative Results+/Under Consideration ImipramineBupropion DesipramineModafinil TyrosineTopirimate OndansetronDisulfiram FluoxetineLobeline AripiprazoleGabapentin

FDA-Approved Meds Lacking There are no FDA-approved medications for the following addictive disorders: –Cocaine –Methamphetamine –Marijuana –Pathological Gambling –Sexual Addiction –Compulsive shopping

Co-Occurring Psychiatric D/O and SUD in Adolescents “Potential problems with the diagnostic process increase almost exponentially when substance use disorders and psychiatric disorders occur together.” (Schukit, 2006) Perform comprehensive psychiatric evaluation including SUD screening Obtain info from multiple sources Have a high index of suspicion for SUD co- morbidity when patient not responding to tx

Clinical Management of CODs Individualize and integrate treatment for CODs whenever possible Consider developmental needs and stages Consider random drug testing Consider need for higher level of care Consult addiction medicine specialist if necessary

Medication Management in COD Ambivalence is common re: use of meds in adolescents with SUDs. Q: When to initiate pharmacotherapy when diagnosis is unclear? –With psychosis, moderate to severe depression, or mania, treat sooner Strategies include: -Communicate frequently with caregivers -Verbalize clear expectations (re: medication outcomes, confidentiality) -Assume potential for misuse and drug interactions -Schedule frequent follow-ups

Medication Management in COD For patients with anxiety d/o’s and SUDs: –Try to avoid BDZs –Consider: SSRIs, buspirone, mirtazapine, trazodone, low-dose quetiapine For patients with ADHD and SUD, consider: –Atomoxetine (Strattera) –Bupropion SR or XL (Wellbutrin) –Modafinil (Provigil) –If stimulant necessary: Long-acting formulations (e.g., Concerta) Lisdexamphetamine Daytrana patch

In Conclusion Addiction is a serious, chronic and relapsing disorder, but treatments are available Medications should be considered as part of a comprehensive treatment plan, addressing both disordered physiology and disrupted lives Medications should be considered for treatment of: psychiatric sx’s, addictive d/o’s, and co- occurring d/o’s Emerging literature supports use of meds in youth with SUDs and psychiatric comorbidity

References Deas D, May MP, Randall C, Johnson N, and Anton R, Naltrexone treatment of adolescents: an open-label pilot study. J Child Adol Psychopharmacol 15(5): Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, Stone C, Samuels D, Levin SK, Green S, and Schatzberg AF, Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol 72(4): Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, and Brooklyn J, Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry 62(10): Monuteaux MC, Spencer TJ, Faraone SV, Wilson AM, and Biederman J, A randomized, placebo-controlled trial of bupropion for the prevention of smoking in children and adolescents with ADHD. J Clin Psychiatry 68(7):

References Muramoto ML, Leischow SJ, Sherrill D, Matthews E, and Strayer LJ, Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. Arch Pediatr Adolesc Med 161(11): Newton TF, Roache JD, De La Garza R 2 nd, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, and Kahn R, Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 31(7): Niederhofer H and Staffen W, 2003a. Acamprosate and its efficacy in treating alcohol dependent adolescents. Eur Child Adolesc Psychiatry 12(3): Niederhofer H and Staffen W, 2003b. Comparison of disulfuram and placebo in treatment of alcohol dependence in adolescents. Drug and Alcohol Rev 22: Kreek MJ, Schlussman SD, Bart J, LaForge KS, and Butelman ER, Evolving perspectives on neurobiological research on the addictions: celebration of the 30 th anniversary of NIDA. Neuropharmacology 47 Suppl 1:

Thank you! Larissa Mooney, M.D. UCLA Integrated Substance Abuse Programs